Three 8-aminoquinolines from the Walter Reed Army Institute for Research (WRAIR), WR6026, WR238605, and WR242511, strongly inhibited Pneumocystis carinii growth in vitro at 1 ,Lg/nil his activity was similar to that of primaquine. In rat therapy models, the WRAIR compounds affected Pneumocystis pneumonia at doses as low as 0.25 mg/kg (WR242511) or 0.5 mg/kg (WR6026 and WR238605). At these doses, primaquine alone was ineffective as therapy. In a rat prophylaxis model, all three WRAIR 8-aminoquinolines were extremely effective at daily doses of 0.57 mg/kg, showing activity greater than that of primaquine at this dosage and comparable to that of trimethoprim-sulfamethoxazole at 50/250 mg/kg.
In the United States, Pneumocystis carinii causes pneumonia in 60 to 80% of individuals infected with the human immunodeficiency virus. Traditional therapeutic and prophylactic regimens, including trimethroprim-sulfamethoxazole and pentamidine, can cause severe adverse reactions in this group of patients. The search for alternative drugs that are effective against P. carinii led to the discovery that the drug combination clindamycin-primaquine is effective both in vitro and in animal models for both therapy and prophylaxis (11) . The combination proved effective in animals, although neither drug was effective alone. The regimen has been carried on to clinical therapy trials (6, 12, 13) and appears to be very effective for the treatment of P. carinii pneumonia. Results of clinical studies carried out by E. Toma in Montreal, Quebec, Canada, in which clindamycinprimaquine was compared with trimethoprim-sulfamethoxazole have not yet been published. Studies of other 8-aminoquinolines related to primaquine were undertaken to find agents with efhanced effectiveness, less toxicity than primaquine, or both.
Many 8-aminoquinolines have been synthesized and tested for activity against protozoal infectiws.jThe Walter Reed Army Institoe for Research (WRAIRJ has actively pursued the develboment of 8-aminoquinolines for antimalarial and antileishmnailial activities (8) . Three WRAIR compounds were selected that were more potent antimalarial agents than primaquine qnd for which pharmacologic and toxicologic data were avaita'ble (3) . Compound WR6026 has entered phase II testing in humans for leishmaniasis, and WR238605 is being considered for phase I and II testing in humans as an antimalarial agent. In animals, WR242511 has been more active against malaria than WR6026 or WR238605 has, but it has a greater potential for producing methemoglobinemia. The advanced state of development of the drugs made them appealing as candidates for testing against P. carinii.
* Corresponding author.
MATERIALS AND METHODS
The in vitro culture system for evaluating compounds for anti-P. carinii activity has been described previously (2) . Briefly, 24-well tissue culture plates (Coming) containing confluent monolayers of WI-38 human embryonic lung fibroblasts in minimum essential medium (Sigma) with 10% fetal bovine serum (Whittaker M.A. Bioproducts) were inoculated with approximately 7 x 105 P. cariniii trophozoites per well. The drugs to be tested were added to the wells so that for each drug concentration there were four wells to be examined at each of five time points. Wells with no drugs and wells with trimethoprim-sulfamethoxazole at 50/250 jxg/ml were included as controls. Plates were incubated at 35°C in an atmosphere of 5% 02 and 10% C02, with the balance being N2. On days 1, 3, 5, 7, and 10, 10-,u samples were removed from the wells, placed on glass slides in 1-cm2 areas, stained with Giemsa, and examined microscopically at x 1,000. P. carinii trophozoites and cysts as well as tissue culture cells were counted in 10 randomly selected fields of unknown slides by two individuals. For each time point, there were eight evaluations (four wells x two examiners) from which means and standard errors were calculated and plotted to provide growth curves.
Inocula for cultures and for animals were prepared from infected rat lungs. Samples of lungs known to be infected, as determined by examination of Giemsa-stained impression smears, were ground in a Ten-Broeck homogenizer in minimum essential medium, and centrifuged slowly (250 x g) to settle the lung pieces, and the supernatant was decanted. A 10-,ul sample of supernatant was stained with Giemsa as well as with viability stain (5) and examined microscopically. The number of trophozoites per milliliter was determined, and the inoculum was adjusted as necessary.
Animal models. Animal models were used both at Indiana University (IU) and the University of North Carolina (UNC). Since the models differed in several aspects, each model is described below.
(i) Animal models at IU. For the transtracheally inoculated rat model for treatment or prophylaxis (1), virus-free female rats (weight, 120 to 140 g; Harlan-Sprague-Dawley, barrier 202, in Indianapolis, Ind.) which were also free of P. carinii 
RESULTS
In vitro cultures showed that all three compounds inhibited P. carinii at 10 and 1 ,ug/ml; they were still somewhat inhibitory at 0.1 ,ug/ml (Fig. 1) . In one experiment, compound 242511 appeared to be very effective at 0.1 jig/ml. This level of activity was similar to that observed previously for primaquine (11) .
In vivo therapy studies with all three compounds were performed at doses of 2.0 mg/kg, because this was the dose of primaquine that was effective in combination with clindamycin for therapy in rats (11) . In all studies scores for both Giemsa-and silver-stained slides are shown because different features are emphasized. Giemsa stain shows the higher scores for trophozoites, and silver stain may detect rare cysts.
In the first therapy study, which was done at IU, we used immunosuppression with dexamethasone and drug treatnosuppression was with dexamethasone. The compounds ment by gavage once per day. All three drugs were effective were active at 0.25 mg/kg/day for WR242511 and 0.5 mg/kg/ ( Table 1 ). Animals that received clindamycin at 225 mg/kg in day for WR6026 and WR238605. addition to the 8-aminoquinolines-once per day by gavage
The three drugs were also tested at IU for their effectivehad scores similar to those of the groups that received ness in prophylaxis (Table 5 ). Drugs were given in the 8-aminoquinolines alone (data not shown).
drinking water, and immunosuppression was with dexameth-A second qudy was performed at both IU and UNC by asone. All three compounds were effective at 0.57 mg/kg/day.
using their respective models. The data from the study
In a separate study, primaquine also was tested in a performed at IU are shown in Table 2 . Animals were immuprophylaxis model of rats immunosuppressed with cortisone nosuppressed with cortisone acetate, and drug doses were acetate given subcutaneously with and without glindamycin given in drinking water. Again, all three drugs were effective. at 225 mg/kg/day in drinking water (Table 6 ). Primaquine In the comparaule study at UNC, the same lots of drugs showed minimal effectiveness when used alone at a dose of provided by WRAIR to IU were used. Table 3 shows the 0.57 mg/kg/day but was quite effective when used at this results of the study done at UNC by using their scoring dose in combination with clindamycin. system. The findings are comparable to those obtained at IU.
A third therapy study was performed at IU to establish the DISCUSSION lowest effective doses of the compounds (Table 4) . The protocol was similar to that used in the second study (Table   Results of the studies done at IU and UNC establish the 2); drug doses were given in the drinking water, and immuefficacy of the 8-aminoquinolines WR238605, WR242511, a Results are expressed as means ± standard errors. The scores are described in the text. b Total is the number of rats for which evaluable slides were obtained; animals that died during the study were not always evaluable. a Results are expressed as means + standard errors. The scores are described in the text. b p < 0.001 compared with untreated controls. C Three rats in the group treated with WR242511 and two untreated rats died soon after the start of the experiment; neither drug therapy nor P. carinii infection appeared to be contributing factors.
and WR6026 for the treatment of Pneumocystis pneumonia. These three compounds were effective for treatment at doses of 1 mg/kg/day or less (1.7 to 2.4 ,umol/kg/day), whereas primaquine was somewhat effective at 2 mg/kg/day (4.4 ,umol/kg/day) and showed better activity at this dose when combined with clindamycin at a dose of 225 mg/kg/day.
Results of the second and third of the three therapy studies were comparable (Tables 2 and 4 ). In both of these studies, drugs were given in drinking water. In the first therapy study (Table 1) , the drugs were less effective, although their effectiveness was clearly different from that of the control, possibly because the drugs were given by gavage in a single daily dose. In earlier experiments (unpublished data) we observed that clindamycin is effective in combination with primaquine when given continuously in water but is ineffective when given once daily by gavage.
The models for animal studies at IU and UNC differed in several significant ways. IU used smaller female rats, while UNC used older, heavier male rats. No study has specifically addressed the susceptibility of rats to either P. carinii infection or immunosuppression related to the age and sex of the animals, although it is known that sex hormones can affect the immune response (9) . At IU, animals received a regular diet, while at UNC animals received a low-protein diet. Diarrhea was noted in the clindamycin-treated rats at UNC (Table 7) , while none was detected at IU. The diarrhea noted at UNC might have been related to the low-protein diet, the different intestinal flora of the rats, or both. In clinical trials with the combination of clindamycin and primaquine, diarrhea has not been a significant problem.
Finally, although there were many differences in the animal models, including sex, body size, diet, source of P. carinii, and evaluation systems, both models yielded comparable evaluations of these drugs for therapy.
Compounds WR6026, WR238605, and WR242511 also were effective for prophylaxis against Pneumocystis pneumonia when given continuously at daily doses of 0.57 mg/kg (1.4, 0.98, and 1 ,umol/kg, respectively) ( Table 5 ). At that same dose, primaquine alone (1.25 ,umol/kg) showed only a weak effect but was effective in combination with clindamycin ( Table 6) .
For prophylaxis the 8-aminoquinolines were used at doses of 0.57 mg/kg, because a previous study (11) showed that this dose of primaquine combined with clindamycin at 225 mg/kg effectively prevented the development of P. carinii pneumonia. In the clindamycin-primaquine prophylaxis study ( frequent consequence of primaquine therapy, and hemolysis may occur in patients with glucose 6-phosphate dehydrogenase deficiency. The WRAIR compounds have less of a potential than primaquine to cause methemoglobinemia because they can be used at much lower doses than primaquine can.
The rat model has predicted the usefulness of a number of drugs for treatment and prophylaxis of Pneumocystis pneumonia (4, 7, 10) . The successful treatment and prophylaxis studies reported here suggest that clinical evaluations of these interesting orally administered compounds should be considered.
